Related references
Note: Only part of the references are listed.Five-Year Outcomes From the Randomized, Phase III Trials CheckMate O17 and O57: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer (vol 39, pg 723, 2021)
Borghaei
JOURNAL OF CLINICAL ONCOLOGY (2021)
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
Luis Paz-Ares et al.
LANCET ONCOLOGY (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Cost-effectiveness of Nivolumab-Ipilimumab Combination Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer
P. Travis Courtney et al.
JAMA NETWORK OPEN (2021)
Cost-Effectiveness of Nivolumab Plus Ipilimumab Combined with Two Cycles of Chemotherapy as First-Line Treatment in Advanced Non-Small Cell Lung Cancer
Ye Peng et al.
ADVANCES IN THERAPY (2021)
Cost-effectiveness of Nivolumab in Patients With NSCLC in the United States
Mohammad A. Chaudhary et al.
AMERICAN JOURNAL OF MANAGED CARE (2021)
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer
Hossein Borghaei et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1.
Suresh S. Ramalingam et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer The MYSTIC Phase 3 Randomized Clinical Trial
Naiyer A. Rizvi et al.
JAMA ONCOLOGY (2020)
Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective
Casey Quinn et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced NSCLC
Jiahao Li et al.
IMMUNOTHERAPY (2020)
Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab vs. Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer
Huabin Hu et al.
FRONTIERS IN ONCOLOGY (2020)
Advances in Targeted Therapy and Immunotherapy for Non-small Cell Lung Cancer Based on Accurate Molecular Typing
Jingsi Dong et al.
FRONTIERS IN PHARMACOLOGY (2019)
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Tony S. K. Mok et al.
LANCET (2019)
Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment
Narjust Duma et al.
MAYO CLINIC PROCEEDINGS (2019)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Cost-effectiveness of pembrolizumab in combination with chemotherapy versus chemotherapy and pembrolizumab monotherapy in the first-line treatment of squamous non-small-cell lung cancer in the US
Ralph P. Insinga et al.
CURRENT MEDICAL RESEARCH AND OPINION (2019)
Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study
Scott Gettinger et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Spencer C. Wei et al.
CANCER DISCOVERY (2018)
Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the US
Ralph P. Insinga et al.
JOURNAL OF MEDICAL ECONOMICS (2018)
Extrapolating Survival from Randomized Trials Using External Data: A Review of Methods
Christopher Jackson et al.
MEDICAL DECISION MAKING (2017)
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer
D. P. Carbone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States
Min Huang et al.
PHARMACOECONOMICS (2017)
Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses Second Panel on Cost-Effectiveness in Health and Medicine
Gillian D. Sanders et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-κB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer
Jin Peng et al.
CANCER RESEARCH (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
An international comparison of costs of end-of-life care for advanced lung cancer patients using health administrative data
Karen E. Bremner et al.
PALLIATIVE MEDICINE (2015)
Combination Therapy with Anti-CTLA-4 and Anti-PD-1 Leads to Distinct Immunologic Changes In Vivo
Rituparna Das et al.
JOURNAL OF IMMUNOLOGY (2015)
Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer
L. Bracci et al.
CELL DEATH AND DIFFERENTIATION (2014)
Response to ''Survival Analysis and Extrapolation Modeling of Time-to-Event Clinical Trial Data for Economic Evaluation: An Alternative Approach'' by Bagust and Beale
Nicholas R. Latimer
MEDICAL DECISION MAKING (2014)
Survival Analysis for Economic Evaluations Alongside Clinical Trials-Extrapolation with Patient-Level Data: Inconsistencies, Limitations, and a Practical Guide
Nicholas R. Latimer
MEDICAL DECISION MAKING (2013)
Share Paper
